In silico approach for the development of novel antiviral compounds based on SARS-COV-2 protease inhibition.

Nickcovic, Vanja P; Nikolic, Gordana R; Nedeljkovic, Biserka M; Mitic, Nebojsa; Danic, Snezana Filipovic; Mitic, Jadranka; Marcetic, Zoran; Sokolovic, Dusan; Veselinovic, Aleksandar M

Nickcovic, Vanja P; Nikolic, Gordana R; Nedeljkovic, Biserka M; Mitic, Nebojsa; Danic, Snezana Filipovic; Mitic, Jadranka; Marcetic, Zoran; Sokolovic, Dusan; Veselinovic, Aleksandar M.

Afiliación

Nickcovic VP; Clinical-Hospital Center, Pristina, Gracanica Serbia.
Nikolic GR; Medical Faculty, University of Pristina, Kosovska Mitrovica, Serbia.
Nedeljkovic BM; Medical Faculty, University of Pristina, Kosovska Mitrovica, Serbia.
Mitic N; Medical Faculty, University of Pristina, Kosovska Mitrovica, Serbia.
Danic SF; Medical Faculty, University of Pristina, Kosovska Mitrovica, Serbia.
Mitic J; Medical Faculty, University of Pristina, Kosovska Mitrovica, Serbia.
Marcetic Z; Medical Faculty, University of Pristina, Kosovska Mitrovica, Serbia.
Sokolovic D; Department of Biochemistry, Faculty of Medicine, University of Nis, Nis, Serbia.
Veselinovic AM; Department of Chemistry, Faculty of Medicine, University of Nis, Bulevar Dr Zorana Dindica 81, 18000 Nis, Serbia.

Chem Zvesti ; 76(7): 4393-4404, 2022.

Article en En | MEDLINE | ID: mdl-35400796

Palabras clave

3CLpro inhibitors; COVID-19 therapy; Drug design; Molecular modeling; QSAR

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Chem Zvesti Año: 2022 Tipo del documento: Article Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google